These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 35426112)
1. Biologics in the Treatment of Uveitis. Dingerkus VLS; Becker MD; Doycheva D Klin Monbl Augenheilkd; 2022 May; 239(5):686-694. PubMed ID: 35426112 [TBL] [Abstract][Full Text] [Related]
2. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625 [TBL] [Abstract][Full Text] [Related]
3. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Thomas AS Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945 [TBL] [Abstract][Full Text] [Related]
4. Expert opinion on the use of biological therapy in non-infectious uveitis. Touhami S; Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D Expert Opin Biol Ther; 2019 May; 19(5):477-490. PubMed ID: 30888881 [TBL] [Abstract][Full Text] [Related]
5. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907 [TBL] [Abstract][Full Text] [Related]
6. Advancements in the management of uveitis. Schwartzman S Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):304-315. PubMed ID: 27886802 [TBL] [Abstract][Full Text] [Related]
7. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359 [TBL] [Abstract][Full Text] [Related]
8. The current status of biological treatment for uveitis. Gaggiano C; Sota J; Gentileschi S; Caggiano V; Grosso S; Tosi GM; Frediani B; Cantarini L; Fabiani C Expert Rev Clin Immunol; 2020 Aug; 16(8):787-811. PubMed ID: 32700605 [TBL] [Abstract][Full Text] [Related]
9. [Therapy for childhood uveitis: biologics: too often--too late?]. Mackensen F; Lutz T Ophthalmologe; 2011 Mar; 108(3):213-21. PubMed ID: 21350869 [TBL] [Abstract][Full Text] [Related]
10. [Biologics in uveitis]. Feurer E; Bielefeld P; Saadoun D; Sève P Rev Med Interne; 2015 Feb; 36(2):107-16. PubMed ID: 25239400 [TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor-α therapy in uveitis. Cordero-Coma M; Sobrin L Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735 [TBL] [Abstract][Full Text] [Related]
12. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital]. Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230 [TBL] [Abstract][Full Text] [Related]
13. Indications and effects of biological agents in the treatment of noninfectious uveitis. Li B; Yang L; Bai F; Tong B; Liu X Immunotherapy; 2022 Aug; 14(12):985-994. PubMed ID: 35695019 [TBL] [Abstract][Full Text] [Related]
14. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. Gupta S; Shyamsundar K; Agrawal M; Vichare N; Biswas J J Ocul Pharmacol Ther; 2022 Apr; 38(3):203-222. PubMed ID: 35133890 [TBL] [Abstract][Full Text] [Related]
15. Perspectives for immunotherapy in noninfectious immune mediated uveitis. Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142 [No Abstract] [Full Text] [Related]
16. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab. Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278 [No Abstract] [Full Text] [Related]
17. Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal. Sharma S; Kharel R; Parajuli S; Jha S Ann Med Surg (Lond); 2023 May; 85(5):1486-1489. PubMed ID: 37229040 [TBL] [Abstract][Full Text] [Related]
18. The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. Lerman MA; Rabinovich CE Paediatr Drugs; 2015 Aug; 17(4):283-301. PubMed ID: 25893479 [TBL] [Abstract][Full Text] [Related]
19. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Benitah NR; Sobrin L; Papaliodis GN Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults. Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]